Cargando…

Management and outcome of topical beta-blockerinduced atrioventricular block

BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Özcan, Kazım Serhan, Güngör, Barış, Tekkeşin, Ahmet İlker, Altay, Servet, Ekmekçi, Ahmet, Toprak, Ercan, Yıldırım, Ersin, Çalık, Nazmi, Alper, Ahmet Taha, Gürkan, Kadir, Erdinler, İzzet, Osmonov, Damirbek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Clinics Cardive Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780015/
https://www.ncbi.nlm.nih.gov/pubmed/26659434
http://dx.doi.org/10.5830/CVJA-2015-030
_version_ 1782419698117246976
author Özcan, Kazım Serhan
Güngör, Barış
Tekkeşin, Ahmet İlker
Altay, Servet
Ekmekçi, Ahmet
Toprak, Ercan
Yıldırım, Ersin
Çalık, Nazmi
Alper, Ahmet Taha
Gürkan, Kadir
Erdinler, İzzet
Osmonov, Damirbek
author_facet Özcan, Kazım Serhan
Güngör, Barış
Tekkeşin, Ahmet İlker
Altay, Servet
Ekmekçi, Ahmet
Toprak, Ercan
Yıldırım, Ersin
Çalık, Nazmi
Alper, Ahmet Taha
Gürkan, Kadir
Erdinler, İzzet
Osmonov, Damirbek
author_sort Özcan, Kazım Serhan
collection PubMed
description BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the Siyami Ersek Training and Research Hospital, between January 2009 and January 2013 with a diagnosis of AV block were included in the study. Subjects using ophthalmic beta-blockers were recruited and followed for permanent pacemaker requirement during hospitalisation and for three months after discontinuation of the drug. A permanent pacemaker was implanted in patients in whom AV block persisted beyond 72 hours or recurred during the follow-up period. RESULTS: A total of 1 122 patients were hospitalised with a diagnosis of AV block and a permanent pacemaker was implanted in 946 cases (84.3%) during the study period. Thirteen patients using ophthalmic beta-blockers for the treatment of glaucoma and no other rate-limiting drugs were included in the study. On electrocardiography, eight patients had complete AV block and five had high-degree AV block. The ophthalmic beta-blockers used were timolol in seven patients (55%), betaxolol in four (30%), and cartelol in two cases (15%). The mean duration of ophthalmic beta-blocker treatment was 30.1 ± 15.9 months. After drug discontinuation, in 10 patients the block persisted and a permanent pacemaker was implanted. During follow up, one more patient required pacemaker implantation. Therefore in total, pacemakers were implanted in 11 out of 13 patients (84.6%). The pacemaker implantation rate did not differ according to the type of topical beta-blocker used (p = 0.37). The presence of infra-nodal block on electrocardiography was associated with higher rates of pacemaker implantation. CONCLUSION: Our results indicate that topical beta-blockers for the treatment of glaucoma may cause severe conduction abnormalities and when AV block occurs, pacemaker implantation is required in a high percentage of the patients.
format Online
Article
Text
id pubmed-4780015
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Clinics Cardive Publishing
record_format MEDLINE/PubMed
spelling pubmed-47800152016-03-21 Management and outcome of topical beta-blockerinduced atrioventricular block Özcan, Kazım Serhan Güngör, Barış Tekkeşin, Ahmet İlker Altay, Servet Ekmekçi, Ahmet Toprak, Ercan Yıldırım, Ersin Çalık, Nazmi Alper, Ahmet Taha Gürkan, Kadir Erdinler, İzzet Osmonov, Damirbek Cardiovasc J Afr Cardiovascular Topics BACKGROUND: Topical beta-blockers have a well-established role in the treatment of glaucoma. We aimed to investigate the outcome of patients who developed symptomatic atrioventricular (AV) block induced by topical beta-blockers. METHODS: All patients admitted or discharged from our institution, the Siyami Ersek Training and Research Hospital, between January 2009 and January 2013 with a diagnosis of AV block were included in the study. Subjects using ophthalmic beta-blockers were recruited and followed for permanent pacemaker requirement during hospitalisation and for three months after discontinuation of the drug. A permanent pacemaker was implanted in patients in whom AV block persisted beyond 72 hours or recurred during the follow-up period. RESULTS: A total of 1 122 patients were hospitalised with a diagnosis of AV block and a permanent pacemaker was implanted in 946 cases (84.3%) during the study period. Thirteen patients using ophthalmic beta-blockers for the treatment of glaucoma and no other rate-limiting drugs were included in the study. On electrocardiography, eight patients had complete AV block and five had high-degree AV block. The ophthalmic beta-blockers used were timolol in seven patients (55%), betaxolol in four (30%), and cartelol in two cases (15%). The mean duration of ophthalmic beta-blocker treatment was 30.1 ± 15.9 months. After drug discontinuation, in 10 patients the block persisted and a permanent pacemaker was implanted. During follow up, one more patient required pacemaker implantation. Therefore in total, pacemakers were implanted in 11 out of 13 patients (84.6%). The pacemaker implantation rate did not differ according to the type of topical beta-blocker used (p = 0.37). The presence of infra-nodal block on electrocardiography was associated with higher rates of pacemaker implantation. CONCLUSION: Our results indicate that topical beta-blockers for the treatment of glaucoma may cause severe conduction abnormalities and when AV block occurs, pacemaker implantation is required in a high percentage of the patients. Clinics Cardive Publishing 2015 /pmc/articles/PMC4780015/ /pubmed/26659434 http://dx.doi.org/10.5830/CVJA-2015-030 Text en Copyright © 2015 Clinics Cardive Publishing http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cardiovascular Topics
Özcan, Kazım Serhan
Güngör, Barış
Tekkeşin, Ahmet İlker
Altay, Servet
Ekmekçi, Ahmet
Toprak, Ercan
Yıldırım, Ersin
Çalık, Nazmi
Alper, Ahmet Taha
Gürkan, Kadir
Erdinler, İzzet
Osmonov, Damirbek
Management and outcome of topical beta-blockerinduced atrioventricular block
title Management and outcome of topical beta-blockerinduced atrioventricular block
title_full Management and outcome of topical beta-blockerinduced atrioventricular block
title_fullStr Management and outcome of topical beta-blockerinduced atrioventricular block
title_full_unstemmed Management and outcome of topical beta-blockerinduced atrioventricular block
title_short Management and outcome of topical beta-blockerinduced atrioventricular block
title_sort management and outcome of topical beta-blockerinduced atrioventricular block
topic Cardiovascular Topics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780015/
https://www.ncbi.nlm.nih.gov/pubmed/26659434
http://dx.doi.org/10.5830/CVJA-2015-030
work_keys_str_mv AT ozcankazımserhan managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT gungorbarıs managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT tekkesinahmetilker managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT altayservet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT ekmekciahmet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT toprakercan managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT yıldırımersin managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT calıknazmi managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT alperahmettaha managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT gurkankadir managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT erdinlerizzet managementandoutcomeoftopicalbetablockerinducedatrioventricularblock
AT osmonovdamirbek managementandoutcomeoftopicalbetablockerinducedatrioventricularblock